Massive study checks if diabetes drug lives up to hype in real world

NCT ID NCT03363464

First seen Jan 18, 2026 · Last updated May 14, 2026 · Updated 16 times

Summary

This study looked at whether the diabetes drug empagliflozin (Jardiance) is as safe and effective in everyday patients as it was in earlier clinical trials. Researchers tracked over 230,000 adults with type 2 diabetes who started taking empagliflozin or a similar drug. The goal was to see if the drug's benefits—like lower risk of heart problems and death—hold up outside of controlled research settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bringham Women Hospital

    Boston, Massachusetts, 02120, United States

Conditions

Explore the condition pages connected to this study.